After Mexican Marketing Deal, Korea's Boryung Ventures Into Central And South America
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Following a similar deal with Mexico-based Stendhal International in January, Boryung Pharmaceutical Co. said it is close to signing marketing agreements for its angiotensin receptor blocker Kanarb (fimasartan) in 12 other Central and South American countries